BFG
PRLD icon

Bleakley Financial Group’s Prelude Therapeutics PRLD Stock Holding History

Bleakley Financial Group’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-22,325
Closed -$135K – 945
2022
Q4 		$135K Buy
+22,325
New +$143K ﹤0.01% 814

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bleakley Financial Group's PRLD Position: Q1 2023 in Review

Bleakley Financial Group sold out of Prelude Therapeutics (PRLD) in Q1 2023, closing a stake of 22,325 shares — an estimated $135K sold.

Bleakley Financial Group first reported a position in PRLD in Q4 2022 and held it in 1 quarter. The position peaked at $135K in Q4 2022. 54 funds tracked by Wall St. Rank hold PRLD as of Q1 2023.

  • Bleakley Financial Group reported no remaining Prelude Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Bleakley Financial Group sold 22,325 Prelude Therapeutics shares in Q1 2023, an estimated $135K.
  • Bleakley Financial Group first reported a position in Prelude Therapeutics in Q4 2022 and held it in 1 quarter.
  • Bleakley Financial Group's Prelude Therapeutics position peaked at $135K in Q4 2022.
  • 54 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2023.

Based on Bleakley Financial Group's 13F filing for Q1 2023, filed 12 May 2023.